FDA Restricts Use of J&J COVID-19 Vaccine after New Evaluation of TTS Risk
Administration of the J&J vaccine is now limited to those aged ≥18 years who cannot access other COVID-19 vaccines or are unable to receive them.
Study Author Reviews Results: Trends in Time to Initiation of Second-line T2D Treatment
Initiation of second-line type 2 diabetes treatment is lagging while A1c at the time it is introduced is climbing. The author of a new study highlights his findings on clinical inertia.
New Findings Suggest Need for Sex-specific Strategies to Prevent Heart Attacks in Young Adults
Seven risk factors accounted for 85% of the risk of first acute myocardial infarction in young adults in a new study.
Dapagliflozin Now Poised to Treat HF Across Full Spectrum of Disease: DELIVER Phase 3 Top Line Findings
High-level results show the trial met its composite primary endpoint, lowering risk of CV death or worsening disease in patients with HFmrEF/HFpEF.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of May 4, 2022
Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
When Does Cannabis Use Become Addictive? Expert Explains How to Help Patients Navigate This Grey Area
As more states legalize cannabis for recreational purposes, it is critical for clinicians to help patients safely navigate its use.
Black Patients with AF Often Don't Receive Anticoagulant at Hospital Discharge, Study Suggests
Black patients hospitalized with atrial fibrillation were 25% less likely to receive oral anticoagulants upon discharge according to a large national registry study.
SGLT-2 Inhibitor and GLP-1 Receptor Agonist Prescribing Trends 2015-2020
PCPs and internists accounted nationally for 57% of SGLT2i and 52% of GLP1RA prescriptions in 2020, more than any other specialty, according to new research.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of May 3, 2022
Intranasal Insulin Could Help Slow Age-related Cognitive Decline, Suggests a New Study
Treatment with intranasal insulin improved executive function and verbal memory, as well as other measures, in participants with and without type 2 diabetes.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of May 2, 2022
Study: Investigational RSV Vaccine Elicited Neutralizing Antibody Responses in Pregnant Women
Results from a phase 2b trial showed that a bivalent RSV prefusion F protein-based vaccine was safe and led to higher neutralizing antibody responses in pregnant women.
FDA Approves Mavacamten, First-in-Class Treatment for Obstructive Hypertrophic Cardiomyopathy
The cardiac myosin inhibitor is the only treatment that targets the pathophysiology of the disease, improving patient function and symptoms.
Detox, Withdrawal, Rehab, Relapse: The Experience of Heavy Drinkers
Approximately one-third of survey respondents with AUD relapsed within 1 year of stopping. Find a profile here of the experience of recovery from those who are trying.
Novel Once-Weekly Insulin Icodec Found Superior vs Insulin Degludec in Reducing HbA1c in Type 2 Diabetes
The ONWARDS 2 trial achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 26 with insulin icodec vs insulin degludec.
Adults with Asthma Found at Higher Risk for Obesity in International Study
The observational study found that longer duration of disease conferred a 32% greater risk of obesity and that nonatopic asthma carried at 47% greater risk.
Talking Cannabis & Brain Health: Why One Expert Says Not to Condemn Use
When talking to younger cannabis users, Henry Mahncke, PhD, says it is important to first understand the underlying causes of use before counseling against it.
Remdesivir Wins FDA Approval for Treatment of COVID-19 in Youngest Patients
The US FDA expanded approval of remdesivir this week to include pediatric patients aged 28 days and older, the first COVID-19 treatment indicated for this population.
Tirzepatide Yields Top Weight Loss of 20% or More in SURMOUNT Clinical Trial
Tirzepatide was associated with reductions in body weight of up to 22.5% over 72 weeks in the global phase 3 registration trial.
Moderna Announces Filing for Emergency Use Authorization for its COVID-19 Vaccine in Children Under Age 6 Years
The biotechnology company said on Thursday that similar requests are underway with international regulatory authorities.